The FDA believes the healthcare sector is yet to realize the full potential of DHTs in the detection of diabetes, “especially in diverse populations, particularly racial and ethnic minorities.” The agency sees the technologies as an enabler of the focus on health equity that it laid out in its strategic plan for 2022 to 2025.
Seeking to further the plan, the FDA’s Center for Devices and Radiological Health is collecting responses to 14 questions about the use of DHTs in diabetes detection.
